Annotation Detail
Information
- Associated Genes
- CTLA4
- Associated Variants
- CTLA4 UNKNOWN
- Source Database
- MMMP
- Description
- In a multicenter single-arm phase II trial of ipilimumab (monotherapy) for pretreated advanced melanoma (n=155), the best overall response rate was 5.8% and the disease control rate was 27%. The median overall survival was 10.2 months (7.6-16.3). The Authors state: "Ipilimumab demonstrated clinical activity with encouraging long-term survival in a previously treated advanced melanoma population"
- MMMP State
- uncharacterized
- MMMP Molecule
- CTLA4
- MMMP Relationship
- no relationship with
- MMMP Drug
- Ipilimumab
- MMMP Drug Alias
- CTLA4 antibody (antagonist)
- MMMP Model
- 5
- MMMP Reference
- O'Day S, Ann Oncol 2010, Epub ahead of print
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Ipilimumab | Resitance or Non-Reponse | true |